Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 1,125 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Carcinoma Non-small Cell Lung Cancer Stage IV Clear all
Completed Phase 3 Interventional Results available

A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer

NCT00762034
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Pemetrexed, Paclitaxel, Carboplatin, Bevacizumab
Drug · Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
67
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • Alhambra, California + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 18, 2026, 2:52 AM EDT
Completed Phase 2 Interventional Results available

Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00326599
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, cediranib maleate, gemcitabine hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
154
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 95 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 18, 2026, 2:52 AM EDT
Completed Not applicable Interventional Results available

Cryotherapy in Treating Patients With Primary Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery

NCT00303901
View directory record Official record
Conditions
Lung Cancer, Metastatic Cancer
Interventions
cryosurgery, positron emission tomography
Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 18, 2026, 2:52 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

NCT01933932
View directory record Official record
Conditions
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions
Selumetinib, Docetaxel, Placebo, Pegylated G-CSF
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
17
States / cities
Aurora, Colorado • Pembroke Pines, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 18, 2026, 2:52 AM EDT
Active, not recruiting Phase 1 Interventional

WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases

NCT04197934
View directory record Official record
Conditions
Anaplastic Astrocytoma, IDH-Wildtype, Glioblastoma, IDH-Wildtype, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Central Nervous System, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection - blood samples, Biospecimen Collection - CSF samples, Computed Tomography, EGFR/EGFRvIII Inhibitor WSD0922-FU, Magnetic Resonance Imaging, Therapeutic Conventional Surgery
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2031
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 18, 2026, 2:52 AM EDT
Completed Phase 1 Interventional

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer

NCT02206334
View directory record Official record
Conditions
Male Breast Carcinoma, Prostate Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Prostate Carcinoma, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Prostate Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT)
Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
74
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 18, 2026, 2:52 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

NCT02846792
View directory record Official record
Conditions
ALK Gene Translocation, EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma, ROS1 Gene Translocation, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Nivolumab, Plinabulin
Biological · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 18, 2026, 2:52 AM EDT
Completed Phase 2 Interventional

Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer

NCT00062101
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
erlotinib hydrochloride, celecoxib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2013 · Synced Oct 18, 2026, 2:52 AM EDT
Completed Phase 1 Interventional

Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)

NCT01069328
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Cancer
Interventions
Nexavar (Sorafenib, BAY43-9006), Bevacizumab, Paclitaxel, Carboplatin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Oct 18, 2026, 2:52 AM EDT
Recruiting Phase 2 Interventional

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

NCT06463665
View directory record Official record
Conditions
Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
Interventions
Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel
Biological · Drug
Lead sponsor
Genelux Corporation
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
15
States / cities
Bullhead City, Arizona • Clermont, Florida • Coral Springs, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 18, 2026, 2:52 AM EDT
Completed Phase 2 Interventional

MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer

NCT00799240
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Arm A: Pemetrexed Cisplatin, Arm B Pemetrexed, Cisplatin and MK-0646
Drug
Lead sponsor
University of Kansas
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
Hutchinson, Kansas • Kansas City, Kansas • Topeka, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2014 · Synced Oct 18, 2026, 2:52 AM EDT
Completed Phase 3 Interventional

A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer

NCT00034268
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
LY900003
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
20
States / cities
Hot Springs, Arkansas • Springdale, Arkansas • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 18, 2026, 2:52 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

NCT05609968
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Sacituzumab Govitecan, Pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
16
States / cities
Mobile, Alabama • Oceanside, California • Clermont, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 18, 2026, 2:52 AM EDT
Completed Phase 2 Interventional Results available

A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer

NCT02259582
View directory record Official record
Conditions
Nonsquamous Nonsmall Cell Neoplasm of Lung
Interventions
Pemetrexed, Carboplatin, demcizumab
Drug
Lead sponsor
OncoMed Pharmaceuticals, Inc.
Industry
Eligibility
21 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
18
States / cities
Rancho Mirage, California • San Francisco, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 18, 2026, 2:52 AM EDT
Completed Phase 2 Interventional

A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

NCT01031225
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
STA 9090
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
21
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2014 · Synced Oct 18, 2026, 2:52 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

NCT06644768
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Lung Cancer
Interventions
valemetostat tosylate, pembrolizumab
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
11
States / cities
La Jolla, California • Los Angeles, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 18, 2026, 2:52 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer

NCT00064350
View directory record Official record
Conditions
Lung Cancer
Interventions
Sorafenib, Placebo
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
141
States / cities
Stanford, California • Aurora, Colorado • Boulder, Colorado + 103 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 18, 2026, 2:52 AM EDT
Recruiting Phase 2 Interventional

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT07154290
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
Interventions
Ubamatamab, Marlotamig, Sarilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
17
States / cities
Birmingham, Alabama • Goodyear, Arizona • Irvine, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 18, 2026, 2:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction

NCT00540982
View directory record Official record
Conditions
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
indocyanine green, lidocaine, vinorelbine ditartrate, high performance liquid chromatography, intracellular fluorescence polarization analysis, liquid chromatography, mass spectrometry, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 18, 2026, 2:52 AM EDT
Not listed Phase 2 Interventional

Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00006215
View directory record Official record
Conditions
Lung Cancer
Interventions
filgrastim, docetaxel, vinorelbine tartrate
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
19
States / cities
Modesto, California • Washington D.C., District of Columbia • Riverdale, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 18, 2026, 2:52 AM EDT
Completed Phase 2 Interventional

Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer

NCT00005849
View directory record Official record
Conditions
Lung Cancer
Interventions
bryostatin 1, paclitaxel
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
10
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 18, 2026, 2:52 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer

NCT01297491
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
BKM120
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
32
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 18, 2026, 2:52 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

NCT05789082
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Divarasib, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
16
States / cities
Duarte, California • Huntington Beach, California • Irvine, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 18, 2026, 2:52 AM EDT
Terminated Phase 1 Interventional

Comfort Level of Two Abdominal Compression Methods Used to Hold Patients Still While Undergoing Stereotactic Body Radiation Therapy for Lung Tumors

NCT00866086
View directory record Official record
Conditions
Lung Cancer
Interventions
questionnaire administration, computed tomography, radiation therapy treatment planning/simulation
Other · Procedure · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 18, 2026, 2:52 AM EDT